Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter randomized, open label study to evaluate overall survival with the
Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of
Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer
(aMBC) patients with no approved alternative therapies available.